ANI Pharmaceuticals (NASDAQ:ANIP) VP Sells 500 Shares of Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 500 shares of the firm’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $75.48, for a total value of $37,740.00. Following the transaction, the vice president directly owned 74,424 shares of the company’s stock, valued at approximately $5,617,523.52. This trade represents a 0.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Meredith Cook also recently made the following trade(s):

• On Monday, July 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $81.84, for a total value of $40,920.00.
• On Friday, June 12th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $82.03, for a total value of $41,015.00.

ANI Pharmaceuticals Stock Down 0.5%

Shares of NASDAQ ANIP traded down $0.34 during trading on Thursday, reaching $74.77. The company had a trading volume of 330,039 shares, compared to its average volume of 381,585. ANI Pharmaceuticals, Inc. has a 12-month low of $70.15 and a 12-month high of $99.50. The stock has a market cap of $1.70 billion, a PE ratio of 16.11 and a beta of 0.44. The business’s 50-day moving average is $81.00 and its 200 day moving average is $79.11. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, beating the consensus estimate of $2.04 by $0.17. The firm had revenue of $266.04 million during the quarter, compared to the consensus estimate of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The company’s revenue was up 25.8% on a year-over-year basis. During the same period last year, the company earned $1.80 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities analysts forecast that ANI Pharmaceuticals, Inc. will post 8.03 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ANIP has been the subject of several recent analyst reports. Canaccord Genuity Group decreased their target price on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a report on Monday. Wall Street Zen cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Guggenheim reduced their price target on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a research report on Monday. Finally, Weiss Ratings lowered shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday. Four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $105.83.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its position in ANI Pharmaceuticals by 2.2% during the fourth quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock valued at $103,022,000 after purchasing an additional 27,598 shares during the period. Penn Capital Management Company LLC grew its position in ANI Pharmaceuticals by 2,058.9% in the 4th quarter. Penn Capital Management Company LLC now owns 137,394 shares of the specialty pharmaceutical company’s stock worth $10,858,000 after purchasing an additional 131,030 shares during the period. Hussman Strategic Advisors Inc. bought a new stake in ANI Pharmaceuticals in the 4th quarter worth approximately $2,487,000. Artemis Investment Management LLP purchased a new stake in ANI Pharmaceuticals during the 4th quarter valued at $1,706,000. Finally, CenterBook Partners LP purchased a new stake in ANI Pharmaceuticals during the 4th quarter valued at $1,518,000. 76.05% of the stock is owned by institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.